Roivant Sciences (NASDAQ:ROIV) Hits New 12-Month High Following Analyst Upgrade

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) reached a new 52-week high during mid-day trading on Tuesday after TD Cowen raised their price target on the stock from $50.00 to $55.00. TD Cowen currently has a buy rating on the stock. Roivant Sciences traded as high as $41.62 and last traded at $39.0310, with a volume of 710937 shares. The stock had previously closed at $34.93.

ROIV has been the topic of several other reports. HC Wainwright increased their target price on shares of Roivant Sciences from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday. Guggenheim upped their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group lifted their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday. Sanford C. Bernstein raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, Citigroup upped their price target on shares of Roivant Sciences from $42.00 to $46.00 and gave the company a “buy” rating in a report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.62.

Insider Activity

In other news, Director Melissa B. Epperly sold 17,750 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $34.38, for a total transaction of $610,245.00. Following the completion of the sale, the director owned 16,474 shares in the company, valued at $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the completion of the sale, the insider owned 18,630,739 shares of the company’s stock, valued at approximately $679,649,358.72. The trade was a 0.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 3,055,913 shares of company stock worth $107,261,258. Company insiders own 8.80% of the company’s stock.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant’s Pulmovant unit reported positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The treatment produced a 56.3% placebo-adjusted reduction in pulmonary vascular resistance, supporting the drug’s potential in a serious disease with substantial unmet need. Roivant PHocus study announcement
• Positive Sentiment: Roivant has started the Phase 3 PHrontier trial, advancing mosliciguat toward a potential registration-enabling study. The transition to late-stage development reduces some development uncertainty and increases the potential value of the program. Mosliciguat Phase 3 trial report
• Positive Sentiment: Analysts raised their price targets while maintaining buy ratings: Jefferies increased its target to $52 from $42, and HC Wainwright raised its target to $47 from $41. These revisions indicate increased confidence in Roivant’s pipeline and commercial prospects.
• Positive Sentiment: Unusually heavy call-option activity and reports that hedge-fund holdings rose 41% added to bullish trading momentum, although options activity is a market-positioning signal rather than a fundamental change. Roivant hedge fund holdings report
• Positive Sentiment: Roivant and partner Priovant are also commercializing Lisraya, described as the first oral FDA-approved treatment for dermatomyositis, with a reported list price of $35,000 per 30-day supply. The launch creates another potential revenue stream, though uptake and reimbursement remain important uncertainties.
• Neutral Sentiment: Management presented at the Wells Fargo and Cantor Fitzgerald healthcare conferences, giving investors additional updates on the pipeline and strategy. The available reports do not identify a separate material announcement from those presentations. Cantor Fitzgerald conference transcript

Institutional Trading of Roivant Sciences

A number of large investors have recently made changes to their positions in the company. Morgan Stanley increased its holdings in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock worth $1,266,402,000 after acquiring an additional 14,036,696 shares in the last quarter. Rubric Capital Management LP increased its stake in Roivant Sciences by 14.7% in the 2nd quarter. Rubric Capital Management LP now owns 20,370,336 shares of the company’s stock valued at $229,574,000 after buying an additional 2,603,260 shares during the last quarter. State Street Corp grew its position in shares of Roivant Sciences by 4.8% in the 2nd quarter. State Street Corp now owns 19,773,480 shares of the company’s stock valued at $222,847,000 after acquiring an additional 911,827 shares during the period. California State Teachers Retirement System raised its position in shares of Roivant Sciences by 4,212.2% in the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company’s stock valued at $672,448,000 after purchasing an additional 18,560,434 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in shares of Roivant Sciences by 365.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after buying an additional 8,621,567 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 0.8%

The company has a market cap of $30.20 billion, a price-to-earnings ratio of -78.89 and a beta of 1.12. The business’s 50 day moving average price is $35.56 and its 200-day moving average price is $31.46.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Equities research analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.